Published in Mol Reprod Dev on November 01, 2002
Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest (2006) 1.86
Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm. Br J Pharmacol (2010) 1.45
Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc Natl Acad Sci U S A (2003) 1.12
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A (2009) 1.08
CB2 receptors in reproduction. Br J Pharmacol (2007) 0.96
Anandamide capacitates bull spermatozoa through CB1 and TRPV1 activation. PLoS One (2011) 0.90
Tuning the oviduct to the anandamide tone. J Clin Invest (2006) 0.89
Genetic loss of Faah compromises male fertility in mice. Biol Reprod (2008) 0.87
Differences in the endocannabinoid system of sperm from fertile and infertile men. PLoS One (2012) 0.85
Energetic metabolism and human sperm motility: impact of CB₁ receptor activation. Endocrinology (2010) 0.83
Δ9-Tetrahydrocannabinol (Δ9-THC) attenuates mouse sperm motility and male fecundity. Br J Pharmacol (2012) 0.80
Endocannabinoids are Involved in Male Vertebrate Reproduction: Regulatory Mechanisms at Central and Gonadal Level. Front Endocrinol (Lausanne) (2014) 0.80
Anandamide induces sperm release from oviductal epithelia through nitric oxide pathway in bovines. PLoS One (2012) 0.79
Endocannabinoids and endovanilloids: a possible balance in the regulation of the testicular GnRH signalling. Int J Endocrinol (2013) 0.78
Anandamide levels fluctuate in the bovine oviduct during the oestrous cycle. PLoS One (2013) 0.76
Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. J Assist Reprod Genet (2015) 0.75
From Fertilisation to Implantation in Mammalian Pregnancy-Modulation of Early Human Reproduction by the Endocannabinoid System. Pharmaceuticals (Basel) (2010) 0.75
Heat Sensing Receptor TRPV1 Is a Mediator of Thermotaxis in Human Spermatozoa. PLoS One (2016) 0.75
Role of the endocannabinoid system in the central regulation of nonmammalian vertebrate reproduction. Int J Endocrinol (2013) 0.75
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol (2007) 1.85
Cannabimimetic effects of osteopathic manipulative treatment. J Am Osteopath Assoc (2005) 1.63
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs (2009) 1.42
Live birth following intracytoplasmic sperm injection after a 15-hour weather-related delay in cryopreservation of testicular sperm. Fertil Steril (2005) 1.42
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol (2003) 1.39
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis (2009) 1.35
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
Cannabinergic ligands. Chem Phys Lipids (2002) 1.25
Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat (2009) 1.25
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem (2007) 1.19
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol (2008) 1.18
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci (2003) 1.16
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) (2005) 1.16
Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol (2004) 1.16
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Cannabinoid receptors as therapeutic targets. Curr Pharm Des (2006) 1.13
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Anal Chem (2007) 1.13
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav (2007) 1.13
Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids (2002) 1.12
N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids (2002) 1.11
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther (2008) 1.10
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 1.09
Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology (2005) 1.09
Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem (2005) 1.09
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. J Med Chem (2005) 1.08
Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins Other Lipid Mediat (2006) 1.08
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res (2010) 1.08
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 1.06
CB1 cannabinoid receptor ligands. Mini Rev Med Chem (2005) 1.06
Estradiol production during controlled ovarian hyperstimulation correlates with treatment outcome in women undergoing in vitro fertilization-embryo transfer. Fertil Steril (2006) 1.06
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 1.06
Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med (2008) 1.06
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'. J Exp Biol (2012) 1.05
The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J Biol Chem (2005) 1.05
Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke (2002) 1.04
Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol Biochem Behav (2005) 1.04
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol (2010) 1.04
Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem (2010) 1.03
Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol (2008) 1.02
Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology (Berl) (2009) 1.02
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci (2009) 1.01
Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav (2006) 1.01
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem (2003) 1.01
Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci (2005) 1.00
Regulation of brain anandamide by acute administration of ethanol. Biochem J (2007) 0.99
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain (2012) 0.99
Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One (2007) 0.99
C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. J Med Chem (2007) 0.99
Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor. J Proteome Res (2007) 0.98
Synthesis and characterization of 2-substituted bornane pharmacophores for novel cannabinergic ligands. Tetrahedron Lett (2008) 0.98
A tale of two cells: endocannabinoid-signaling regulates functions of neurons and sperm. Biol Reprod (2005) 0.98
The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism. Biochim Biophys Acta (2005) 0.97
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem (2003) 0.97
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol (2009) 0.97
Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther (2007) 0.97
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 0.97
Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology (Berl) (2004) 0.96
Heteroadamantyl cannabinoids. J Med Chem (2010) 0.96
Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int Rev Psychiatry (2009) 0.96
(R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol (2003) 0.95
Bifunctional agents for reperfusion arrhythmias: novel hybrid vitamin E/class I antiarrhythmics. Bioorg Med Chem (2003) 0.95
From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther (2002) 0.95
CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem (2007) 0.95
Endocannabinoid metabolomics: a novel liquid chromatography-mass spectrometry reagent for fatty acid analysis. AAPS J (2006) 0.95
Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther (2008) 0.94
Exercise-induced endocannabinoid signaling is modulated by intensity. Eur J Appl Physiol (2012) 0.94
Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors. J Pharmacol Exp Ther (2004) 0.94
Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol (2012) 0.94
The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med (2005) 0.93
Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem (2006) 0.93
3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. J Med Chem (2006) 0.93
Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta. Endocrinology (2009) 0.93
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav (2011) 0.93
Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. Bioorg Med Chem Lett (2002) 0.93
The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav (2003) 0.93
Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire. Protein Sci (2013) 0.92
Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorg Med Chem Lett (2007) 0.92